Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry.

BACKGROUND Anti-tumor necrosis factor agents (anti-TNFs) are efficacious at preventing the postoperative recurrence (POR) of Crohn disease, as demonstrated in 2 randomized controlled trials. However, real-life data for infliximab or adalimumab in this setting are scarce. Our aim was to assess both the efficiency of anti-TNFs at preventing early POR of Crohn disease in clinical practice and the associated risk factors for POR. METHODS Patients in whom anti-TNFs were prescribed for the prevention of POR within 3 months after ileocolonic resection and who had an endoscopic assessment within 18 months were identified from the ENEIDA registry. Clinical and endoscopic features were collected within 18 months after surgery. RESULTS In total, 152 patients were included (55 treated with infliximab, 97 with adalimumab, and 39% with concomitant immunosuppressants). Anti-TNF treatment was started after a median time of 29 days (IQR 13-44) after surgery. Eighty-two percent of patients had at least one risk factor for POR, and 82% had been exposed to anti-TNFs before the index surgery. Overall, 34% had endoscopic POR (as defined using a Rutgeerts endoscopic score > i1); 14% had advanced endoscopic POR (>i2); and 20% had clinical POR, with no differences between infliximab and adalimumab. In the multivariate analysis, only perianal disease (odds ratio 2.73, 95% confidence interval [CI] 1.26-5.91) and rectal involvement (odds ratio 2.79, 95% CI 1.09-7.14) were independent predictors of endoscopic POR. CONCLUSIONS In clinical practice, anti-TNFs for the prevention of POR of Crohn disease are frequently used in patients experienced with anti-TNFs and with concomitant immunosuppressants. The efficacy of infliximab and adalimumab for POR prevention is similar and in accordance with the results obtained in randomized controlled trials.

[1]  E. El Rassy,et al.  Comparative Efficacy of Anti-TNF Therapies For The Prevention of Postoperative Recurrence of Crohn’s Disease , 2019, Journal of clinical gastroenterology.

[2]  J. Gisbert,et al.  Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la utilidad de la determinación de calprotectina fecal en la enfermedad inflamatoria intestinal , 2018, Gastroenterología y Hepatología.

[3]  X. Jouven,et al.  Male gender, active smoking and previous intestinal resection are risk factors for post‐operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study , 2018, Alimentary pharmacology & therapeutics.

[4]  D. Sorrentino,et al.  Clinically Significant Small Bowel Crohn's Disease Might Only be Detected by Capsule Endoscopy. , 2018, Inflammatory bowel diseases.

[5]  S. Vermeire,et al.  The operative risk and natural history after the diagnosis of ileal penetrating Crohn’s disease , 2018, European journal of gastroenterology & hepatology.

[6]  J. Llach,et al.  Comparison of Capsule Endoscopy and Magnetic Resonance Enterography for the Assessment of Small Bowel Lesions in Crohn's Disease. , 2018, Inflammatory bowel diseases.

[7]  M. Kanda,et al.  Postoperative adalimumab maintenance therapy for Japanese patients with Crohn’s disease: a single-center, single-arm phase II trial (CCOG-1107 study) , 2018, Surgery Today.

[8]  Mamoru Watanabe,et al.  Postoperative therapy with infliximab for Crohn’s disease: a 2-year prospective randomized multicenter study in Japan , 2018, Surgery Today.

[9]  Jun Kato,et al.  Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease , 2018, Intestinal research.

[10]  J. Gisbert,et al.  Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease , 2018, Gastroenterología y Hepatología (English Edition).

[11]  U. Kopylov,et al.  The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors , 2017, Inflammatory bowel diseases.

[12]  J. Gisbert,et al.  Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn’s Disease Recurrence. A GETECCU Randomised Trial , 2017, Journal of Crohn's & colitis.

[13]  M. Mínguez,et al.  Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicrohn Study , 2017, Inflammatory bowel diseases.

[14]  S. Bonovas,et al.  Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting , 2017, Digestion.

[15]  J. Gisbert,et al.  Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la monitorización, prevención y tratamiento de la recurrencia posquirúrgica en la enfermedad de Crohn , 2017 .

[16]  J. Gisbert,et al.  Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the monitoring, prevention and treatment of post-operative recurrence in Crohn's disease. , 2017 .

[17]  C. Buskens,et al.  3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. , 2017, Journal of Crohn's & colitis.

[18]  L. Peyrin-Biroulet,et al.  Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn’s Disease Recurrence , 2016, Journal of Crohn's & colitis.

[19]  Siddharth Singh,et al.  American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection. , 2017, Gastroenterology.

[20]  A. Ford,et al.  Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis , 2016, Frontline Gastroenterology.

[21]  H. Isomoto,et al.  Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan , 2016, BMC Gastroenterology.

[22]  M. Regueiro,et al.  Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. , 2016, Gastroenterology.

[23]  B. Nørgård,et al.  Postoperative Use of Anti-TNF-&agr; Agents in Patients with Crohn's Disease and Risk of Reoperation—A Nationwide Cohort Study , 2016, Inflammatory bowel diseases.

[24]  M. Kamm,et al.  Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high‐risk patients – a POCER study analysis , 2015, Alimentary pharmacology & therapeutics.

[25]  Steven J Brown,et al.  Crohn's disease management after intestinal resection: a randomised trial , 2015, The Lancet.

[26]  E. Cabré,et al.  Optimizing post-operative Crohn’s disease treatment , 2014, Annals of gastroenterology.

[27]  A. Tursi,et al.  Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn’s disease: an open-label, pilot study , 2014, Techniques in Coloproctology.

[28]  E. Cabré,et al.  An Overview of the Natural History of Inflammatory Bowel Diseases , 2014, Digestive Diseases.

[29]  Koji Tanaka,et al.  The impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn’s disease: a single-center paired case–control study , 2014, Surgery Today.

[30]  L. Guidi,et al.  Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. , 2013, Journal of Crohn's & colitis.

[31]  E. Savarino,et al.  Adalimumab Is More Effective Than Azathioprine and Mesalamine at Preventing Postoperative Recurrence of Crohn's Disease: A Randomized Controlled Trial , 2013, The American Journal of Gastroenterology.

[32]  E. Cabré,et al.  Addition of Metronidazole to Azathioprine for the Prevention of Postoperative Recurrence of Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial , 2013, Inflammatory bowel diseases.

[33]  G. Mantzaris,et al.  Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. , 2012, Journal of Crohn's & colitis.

[34]  H. Ikeuchi,et al.  Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: A 3‐year prospective randomized open trial , 2012, Inflammatory bowel diseases.

[35]  C. Sánchez-Montes,et al.  Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients. , 2012, World journal of gastroenterology.

[36]  E. Savarino,et al.  Adalimumab for the prevention of recurrence after surgery for Crohn’s disease: author’s reply , 2012 .

[37]  H. Ogata,et al.  The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients: a pilot open-labeled prospective study , 2012, International Journal of Colorectal Disease.

[38]  M. Geraci,et al.  Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[39]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[40]  Laurent Beaugerie,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. , 2006, Journal of Crohn's & colitis.

[41]  M. Regueiro,et al.  Infliximab prevents Crohn's disease recurrence after ileal resection. , 2009, Gastroenterology.

[42]  C. Avellini,et al.  Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. , 2007, Archives of internal medicine.

[43]  P. Rutgeerts,et al.  Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. , 1998, Gastroenterology.

[44]  P. Rutgeerts,et al.  Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.